Medical device developer Imricor (IMR) announces first successful ablation procedure since lockdown eased in Europe
2021-02-24 02:11:18 (AET) by Ring Zhang 642
Imricor Medical Systems (ASX: IMR) announced the commencement of procedures at the Netherlands-based Maastricht University Medical Centre+ (MUMC+), following the COVID-19 lockdown measures eased in Europe.
Imricor Medical Systems (ASX: IMR), an ASX-Listed medical device developer specialised in MRI-guided cardiac ablation products, today announced the commencement of procedures at Netherlands-based Maastricht University Medical Centre+ (MUMC+), following the COVID-19 lockdown measures eased in Europe.
The share price of IMR moved up by 1.36% today to $2.23.
The team at MUMC+ has successfully performed two atrial flutter ablation procedures earlier today using the company’s full suite of products, including its prime product Vision-MR Ablation Catheter, in an Interventional Cardiac Magnetic Resonance Imaging (iCMR) lab facility.
MUMC+ Electrophysiologist, Dr. Marisevi Chaldoupi, MD PhD, commented that they realised the limitation in the past, and now can see ‘what we are doing’. He added: “While we have just started in iCMR, it is obvious to see the future of this technology and where it will take us and patient treatment.”
The medical device developer confirmed that it would continue to schedule training and installation at new sites and supporting the recommencement of procedures at existing sites as restrictions associated with COVID-19 started to lift across the globe.
A bit intro about Imricor
Imicor is a leading developer of innovative MRI-compatible medical devices which are used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.
The Vision-MR Ablation Catheter is the Company’s prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters.
Source: IMR ASX announcement MAASTRICHT UNIVERISITY MEDICAL CENTER COMMENCES PROCEDURES